Antiretroviral treatment of HIV infection: Swedish recommendations 2005

Scandinavian Journal of Infectious Diseases

Volumn 38, Issue 2, 2006, Pages 86-103

  Gisslén, Magnus ^a   Ahlqvist Rastad, Jane ^b   Albert, Jan ^c   Blaxhult, Anders ^d   Hamberg, Anna Karin ^b   Lindbäck, Stefan ^d   Sandström, Eric ^e   Uhnoo, Ingrid ^b   Sönnerborg, Anders ^d   Beermann, B ^b   Bergbrant, I M ^a   Berglund, T ^c   Bohlin Wiechel, A B ^d   Brandt, C ^b   Bratt, G ^e   Flamholc, L ^f   Gaines, H ^c   Jonsson, B ^b   Koppel, K ^e   Lidman, K ^g   Lindgren, S ^d   Moberg, L ^d   Morfeldt, L ^d   Nilsson, A ^e   Nilsson Schonesson L ^e   Nilsson, P ^b   Pehrsson, P O ^d   Schvarcz, R ^d   Stahle L ^d   Svennerholm, B ^a   Wahren, B ^c   Wejstal R ^a   Akerlund B ^d   more..

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e STOCKHOLM SÖDER HOSPITAL   (Sweden)

^f LUND UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; BODY DISTRIBUTION; CENTRAL NERVOUS SYSTEM DISEASE; CONJUNCTIVITIS; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EVIDENCE BASED MEDICINE; FATIGUE; FETUS DISEASE; FEVER; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOTENSION; LACTIC ACIDOSIS; LIPOATROPHY; LIVER DYSFUNCTION; LIVER INJURY; LYMPHADENOPATHY; MALAISE; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MOUTH ULCER; MYALGIA; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PATIENT COMPLIANCE; RESPIRATORY TRACT DISEASE; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SWEDEN; TREATMENT FAILURE; TUBERCULOSIS; VOMITING;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FOOD-DRUG INTERACTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; SWEDEN;

EID: 32144434537     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540500388834     Document Type: Article

References (28)

1. Gulick, RM and Ribaudo, HJ and Shikuma, CM and Lustgarten, S and Squires, KE and Meyer, WA, 3rd and (2004) Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection N Engl J Med, 350, pp. 1850-61.
2. Walmsley, S and Bernstein, B and King, M and Arribas, J and Beall, G and Ruane, P and (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection N Engl J Med, 346, pp. 2039-46.
3. DeJesus, E and Herrera, G and Teofilo, E and Gerstoft, J and Buendia, CB and Brand, JD and (2004) Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis, 39, pp. 1038-46.
4. GallantJ, RodriguezA, WeinbergW. Early non-response to tenofovir DF (TDF)+abacavir (ABC) and lamivudine (3TC) in a randomized trial compared to efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. In:43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003. Chicago, IL.
5. Leon, A and Martinez, E and Mallolas, J and Laguno, M and Blanco, JL and Pumarola, T and (2005) Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine Aids, 19, pp. 213-5.
6. Robbins, GK and De Gruttola, V and Shafer, RW and Smeaton, LM and Snyder, SW and Pettinelli, C and (2003) Comparison of sequential 3-drug regimens as initial therapy for HIV-1 infection N Engl J Med, 349, pp. 2293-303.
7. Baylor, MS and Johann-Liang, R. (2004) Hepatotoxicity associated with nevirapine use J Acquir Immune Defic Syndr, 35, pp. 538-9.
8. Wood, R and Phanuphak, P and Cahn, P and Pokrovskiy, V and Rozenbaum, W and Pantaleo, G and (2004) Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir J Acquir Immune Defic Syndr, 36, pp. 684- 92.
9. Cardiello, P.G. and Hassink, E. and Ananworanich, J. and Srasuebkul, P. and Samor, T. and Mahanontharit, A. 2005 A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection Clin Infect Dis, 40, 594-600
10. Lyons, FE and Coughlan, S and Byrne, CM and Hopkins, SM and Hall, WW and Mulcahy, FM. (2005) Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy Aids, 19, pp. 63-7.
11. Nettles, RE and Kieffer, TL and Kwon, P and Monie, D and Han, Y and Parsons, T and (2005) Intermittent HIV-1 viraemia (Blips) and drug resistance in patients receiving HAART Jama, 293, pp. 817-29.
12. Vandamme, A.M. and Sonnerborg, A. and Ait-Khaled, M. and Albert, J and Asjo, B and Bacheler, L and (2004) Updated European recommendations for the clinical use of HIV drug resistance testing Antivir Ther, 9, 829-848
13. Kinloch-de Loes, S and Hoen, B and Smith, DE and Autran, B and Lampe, FC and Phillips, AN and (2005) Impact of therapeutic immunization on HIV-1 viraemia after discontinuation of antiretroviral therapy initiated during acute infection J Infect Dis, 192, pp. 607-617.
14. BangLM, ScottLJ. Emtricitabine: An antiretroviral agent for HIV infection. Drugs 2003; 63:2413-24 discussion 2425-2426
15. PikettyC, PellegrinI, KatlamaC. Efficacy of tenofovir fumarate in hepatits B virus in HIV coinfected pateints: The TECOVIR study. In:11th Conference on Retrovirus and Opportunistic Infections. 2004. San Francisco, CA.
16. Benhamou, Y and Bochet, M and Thibault, V and Di Martino, V and Caumes, E and Bricaire, F and (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients Hepatology 30 1302-1306
17. Angus, P and Vaughan, R and Xiong, S and Yang, H and Delaney, W and Gibbs, C and (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase Gastroenterology, 125, pp. 292-297.
18. Vallet-Pichard, A and Pol, S. (2004) Hepatitis viruses and human immunodeficiency virus coinfection: Pathogenesis and treatment J Hepatol, 41, pp. 156-66.
19. Soriano, V and Puoti, M and Bonacini, M and Brook, G and Cargnel, A and Rockstroh, J and (2005) Care of patients with chronic hepatitis B and HIV coinfection: Recommendations from an HIV-HBV International Panel Aids, 19, pp. 221-40.
20. Benhamou Y, Thibault V, Vig P. Long-term treatment with adefovir dipivoxil 10 mg (ADV) in patients with lamivudine resistant (LAM-R) HBV and HIV coinfection results in significant and sustained clinical improvement. In:15th International Conference of AIDS. 2004. Bangkok, Thailand.
21. Dore, GJ and Cooper, DA and Pozniak, AL and DeJesus, E and Zhong, L and Miller, MD and (2004) Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus J Infect Dis, 189, pp. 1185-1192.
22. Bani-Sadr, F and Palmer, P and Scieux, C and Molina, JM. (2004) 96-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus Clin Infect Dis, 39, pp. 1062-1064.
23. Rey, D. and Krantz, V. and Partisani, M. and Schmitt, M.P. and Meyer, P. and Libbrecht, E. 2000 Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load Vaccine, 18, pp. 1161-1165.
24. Kewn, S and Hoggard, PG and Henry-Mowatt, JS and Veal, GJ and Sales, SD and Barry, MG and (1999) Intracellular activation of 2′,3′-dideoxyinosine and drug interactions in vitro AIDS Res Hum Retroviruses, 15, pp. 793-802.
25. EMEA Public Statement. Important new pharmacokinetic data demonstrating that REYATAZ (atazanavir sulfate) combined with NORVIR (ritonavir) and omeprazole should not be co-administered. p. www.emea.eu.int/pdfs/human/ press/pus/20234904en.pdf.
26. Piscitelli, SC and Burstein, AH and Chaitt, D and Alfaro, RM and Falloon, J. (2000) Indinavir concentrations and St John's Wort Lancet, 355, pp. 547-548.
27. Martin, A and Smith, DE and Carr, A and Ringland, C and Amin, J and Emery, S and (2004) Reversibility of lipoatrophy in HIV-infected patients 2 y after switching from a thymidine analogue to abacavir: The MITOX Extension Study Aids, 18, pp. 1029-1036.
28. Friis-Moller, N and Sabin, CA and Weber, R and d'Arminio Monforte, A and El-Sadr, WM and Reiss, P and (2003) Combination antiretroviral therapy and the risk of myocardial infarction N Engl J Med, 349, pp. 1993-2003.